The FDA approved a supplement to abbreviated new drug application ANDA 078786 for carvedilol on 27 August 2026. An abbreviated application is the route for a generic copy of an already-approved medicine, and a supplement to one is an amendment to an existing marketing authorisation rather than a new product, a new indication or a safety action.
The public record for this action carries the application number and the drug name and nothing about what was changed. It is therefore not a label change, a safety communication or a restriction, and it should not be reported to colleagues as any of those. It is an administrative approval affecting one manufacturer's generic carvedilol.
What it is worth knowing for is supply. Actions on generic applications are the mechanism by which manufacturing sites, presentations and pack sizes change, and those are the changes that show up in clinic as a tablet that looks different or a strength that is briefly hard to obtain. Carvedilol is widely used in India as a generic under several brand names, and the Indian regulatory position is set by CDSCO, not the FDA, so nothing here changes availability or labelling here.
- Nothing in this action changes carvedilol dosing, indications or safety monitoring
- Reassure a patient whose generic carvedilol tablet changes appearance that the medicine is the same and the dose is unchanged
- Keep the usual cautions in mind when prescribing carvedilol: bradycardia, hypotension on uptitration, and caution in reactive airway disease
- Remember that FDA actions do not govern Indian availability, which follows CDSCO
- Check the Drugs@FDA record directly if a specific manufacturing or labelling detail matters to your practice
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free